Evidence map›Paper›PMID 41536023›Full record

ArticleEuropean journal of haematology2026

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal Impairment.

Rintu Sharma, Eshetu G Atenafu, Esther Masih-Khan, Harjot Vohra, Sita Bhella, Christine Chen, Vishal Kukreti, Guido Lancman, Anca Prica, A Keith Stewart and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rintu SharmaPrincess Margaret Cancer Center, Toronto, ON, Canada.ORCID https://orcid.org/0000-0002-3407-1355
Eshetu G AtenafuBiostatistics, University Health Network, Toronto, ON, Canada.
Esther Masih-KhanPrincess Margaret Cancer Center, Toronto, ON, Canada.
Harjot VohraPrincess Margaret Cancer Center, Toronto, ON, Canada.
Sita BhellaPrincess Margaret Cancer Center, Toronto, ON, Canada.
Christine ChenPrincess Margaret Cancer Center, Toronto, ON, Canada.ORCID https://orcid.org/0000-0002-9528-3669
Vishal KukretiPrincess Margaret Cancer Center, Toronto, ON, Canada.
Guido LancmanPrincess Margaret Cancer Center, Toronto, ON, Canada.
Anca PricaPrincess Margaret Cancer Center, Toronto, ON, Canada.
A Keith StewartPrincess Margaret Cancer Center, Toronto, ON, Canada.
Rodger TiedemannUniversity of Auckland, Auckland, New Zealand.
Suzanne TrudelPrincess Margaret Cancer Center, Toronto, ON, Canada.
Chloe YangPrincess Margaret Cancer Center, Toronto, ON, Canada.
Donna ReecePrincess Margaret Cancer Center, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere renal insufficiency requiring dialysis in newly diagnosed multiple myeloma (NDMM) patients has been independently associated with poor survival outcomes. However, there is a paucity of data on factors predicting renal recovery and survival outcomes of these patients.

methodsWe retrospectively analyzed outcomes in NDMM patients presenting with severe dialysis-requiring RI from 01/2010 to 12/2022.

resultsSeventy patients were identified; all receiving novel agent-based induction (bortezomib-based 96%; lenalidomide-based 3%)-73% (n = 51) underwent ASCT. Thirty-three (48%) patients became dialysis independent; early achievement of VGPR in < 4.4 months from treatment initiation was identified as the only factor predicting renal recovery and dialysis withdrawal on univariate analysis (Hazard ratio [HR] of 4.172; p-value = 0.0014). At median follow-up of 39 months, the median overall survival (OS) of dialysis-requiring NDMM patients was 98.3 months with 2- and 5-year OS rates of 84% and 67%, respectively; 2- and 5-year progression-free survival (PFS) rates were 66.9% and 43.7%, respectively. On multivariable analysis, low LDH at diagnosis (HR: 1.003, p = 0.0092), undergoing ASCT (HR: 0.213; p-value = 0.0016), and dialysis independence (HR: 0.311; p-value = 0.0112) independently predicted improved OS.

conclusionsEarly VGPR and hemodialysis independence translated to improved survival, providing a benchmark for future comparison as anti-CD38 monoclonal antibodies enter first line therapy.

Indexed as

Multiple MyelomaRenal DialysisRenal InsufficiencyAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedPrognosisRetrospective Studiesdialysisnewly diagnosed multiple myelomaoutcomesrenal impairmentrenal recoverysurvival

Identifiers

PMID41536023
PMCPMC13050672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.